QSAM Biosciences Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam®
July 13, 2022 13:32 ET
|
QSAM Biosciences, Inc.
AUSTIN, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- via Investorwire -- QSAM Biosciences Inc. (OTCQB: QSAM) (the “Company”), a company developing next-generation targeted therapeutic...
POINT Biopharma to Participate in Upcoming Investor Conferences
July 06, 2022 08:30 ET
|
POINT Biopharma
INDIANAPOLIS, July 06, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT Biopharma announces appointment of Chris Horvath as EVP, Commercial
June 21, 2022 08:30 ET
|
POINT Biopharma
Mr. Horvath will lead the commercialization of POINT’s pipeline. He brings over a decade of experience in pharmaceutical commercialization, most recently as the VP and Head of Prostate Cancer...
POINT Biopharma to Participate in Upcoming Investor Conferences
May 19, 2022 17:30 ET
|
POINT Biopharma
INDIANAPOLIS, May 19, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-α Targeted Clinical Program
May 16, 2022 08:30 ET
|
POINT Biopharma
A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004’s Phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy INDIANAPOLIS,...
POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update
May 13, 2022 08:30 ET
|
POINT Biopharma
POINT's manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled. CTA filed with Health Canada...
Global Peptide Therapeutics Clinical Trials to 2028: Focus on Glucagon-like Peptides, Glycopeptides, Oligopeptides, Lipopeptides, Dipeptides, Opioid, Neuropeptides and Bicyclic Peptides
May 09, 2022 06:28 ET
|
Research and Markets
Dublin, May 09, 2022 (GLOBE NEWSWIRE) -- The "Global Peptide Therapeutics Market & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. The global peptide...
POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002 for the SPLASH Trial
May 05, 2022 09:15 ET
|
POINT Biopharma
INDIANAPOLIS, May 05, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
First European Union Patient Dosed with 177Lu-PNT2002 in the Phase 3 SPLASH Trial
April 26, 2022 08:30 ET
|
POINT Biopharma
POINT Biopharma’s Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now randomizing in the US, Canada, and Europe Sites initiated in France, Sweden,...
QSAM Biosciences Receives Japanese Patent for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®
April 12, 2022 08:00 ET
|
QSAM Biosciences Inc.
Austin, TX, April 12, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...